UFP Technologies delivered results in line with Wall Street’s revenue expectations for Q1 and outperformed on adjusted profitability, driving a positive market reaction. Management attributed the quarter’s growth to strength in medical sales, particularly in robotic surgery, patient surfaces, and interventional segments, which offset declines in nonmedical areas like automotive. CEO Jeff Bailly highlighted the company’s ongoing shift away from nonmedical markets and the ramp-up of four new program launches as key contributors to performance. "Our revenue grew 4.1% with medical sales growing 5.9%," Bailly noted, while acknowledging start-up costs and temporary drags from inventory issues and labor inefficiencies.

Is now the time to buy UFPT? Find out in our full research report (it’s free for active Edge members).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From UFP Technologies’s Q1 Earnings Call

• Brett Fishbin (KeyBanc Capital Markets) asked about growth in the robotics segment and contributions from new product launches. CFO Ronald Lataille explained that current growth is primarily from existing programs, with new launches expected to contribute significantly in the coming quarters.
• Brett Fishbin (KeyBanc Capital Markets) inquired about the ongoing decline in nonmedical business. CEO Jeff Bailly responded that automotive is being phased out, and advanced components will see little to no growth as the company focuses on higher-growth medical markets.
• Justin Ages (CJS Securities) questioned the impact of start-up costs from new program launches on profitability. Lataille clarified that these costs will be absorbed as volumes ramp, with stronger contributions expected in the second half of the year.
• Justin Ages (CJS Securities) asked about capacity expansion in La Romana and Santiago. Lataille detailed the new buildings’ roles and how they will support growth in robotic surgery and patient surfaces, with La Romana focused on robotic surgery due to team expertise.
• Andrew Cooper (Raymond James) sought clarification on the duration of inventory-related slowdowns in wound care. Lataille said the impact should last about three quarters, with normalization and new programs expected to drive growth beyond that period.

Catalysts in Upcoming Quarters

Looking ahead, the StockStory team will be monitoring (1) the successful ramp-up and revenue contribution from the four newly launched medical programs, (2) the operational impact of expanded production capacity in the Dominican Republic and initial plans for Asia-Pacific, and (3) improvements in labor efficiency and backlog reduction at AJR. Progress in these areas, along with ongoing acquisition activity, will be key markers for execution against UFP Technologies’ growth strategy.

UFP Technologies currently trades at $230.53, up from $192.55 just before the earnings. Is there an opportunity in the stock?Find out in our full research report (it’s free).

The Best Stocks for High-Quality Investors

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don't just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn't over. Find out which 9 stocks made the cut this week - FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Exlservice (+354% five-year return). Find your next big winner with StockStory today.